These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9301994)

  • 1. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients.
    Traunmüller F; Schenk P; Mittermeyer C; Thalhammer-Scherrer R; Ratheiser K; Thalhammer F
    J Antimicrob Chemother; 2002 Jan; 49(1):129-34. PubMed ID: 11751776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections.
    Buijk SL; Gyssens IC; Mouton JW; Van Vliet A; Verbrugh HA; Bruining HA
    J Antimicrob Chemother; 2002 Jan; 49(1):121-8. PubMed ID: 11751775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion ceftazidime in intensive care: a randomized controlled trial.
    Lipman J; Gomersall CD; Gin T; Joynt GM; Young RJ
    J Antimicrob Chemother; 1999 Feb; 43(2):309-11. PubMed ID: 11252342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 Aug; 50(2):184-91. PubMed ID: 10930972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion of ceftazidime with an elastomeric infusion device.
    Couldry R; Sanborn M; Klutman NE; Strayer AH
    Am J Health Syst Pharm; 1998 Jan; 55(2):145-9. PubMed ID: 9465978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.
    Joynt GM; Lipman J; Gomersall CD; Young RJ; Wong EL; Gin T
    J Antimicrob Chemother; 2001 Apr; 47(4):421-9. PubMed ID: 11266414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent and continuous ceftazidime infusion for critically ill trauma patients.
    Hanes SD; Wood GC; Herring V; Croce MA; Fabian TC; Pritchard E; Boucher BA
    Am J Surg; 2000 Jun; 179(6):436-40. PubMed ID: 11004326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
    Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
    Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
    Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.
    Nicolau DP; Nightingale CH; Banevicius MA; Fu Q; Quintiliani R
    Antimicrob Agents Chemother; 1996 Jan; 40(1):61-4. PubMed ID: 8787880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
    Lipman J; Wallis SC; Rickard CM; Fraenkel D
    Intensive Care Med; 2001 Feb; 27(2):363-70. PubMed ID: 11396280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis.
    König C; Braune S; Roberts JA; Nierhaus A; Steinmetz OM; Baehr M; Frey OR; Langebrake C; Kluge S
    J Antimicrob Chemother; 2017 May; 72(5):1433-1440. PubMed ID: 28175308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ceftazidime in dogs following subcutaneous administration and continuous infusion and the association with in vitro susceptibility of Pseudomonas aeruginosa.
    Moore KW; Trepanier LA; Lautzenhiser SJ; Fialkowski JP; Rosin E
    Am J Vet Res; 2000 Oct; 61(10):1204-8. PubMed ID: 11039548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.
    Mouton JW; den Hollander JG
    Antimicrob Agents Chemother; 1994 May; 38(5):931-6. PubMed ID: 8067772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Echeverría O; Gómez-Lus ML; Prieto J
    J Antimicrob Chemother; 2005 Feb; 55(2):209-13. PubMed ID: 15650000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 May; 49(5):445-52. PubMed ID: 10792202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.